APLS Apellis Pharmaceuticals Inc

Price (delayed)

$44.15

Market cap

$4.7B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.95

Enterprise value

$4.28B

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, the company aims ...

Highlights
The equity has surged by 133% since the previous quarter
The company's debt fell by 49% YoY
APLS's net income has dropped by 95% year-on-year but it is up by 6% since the previous quarter
The EPS has dropped by 72% year-on-year but it is up by 10% since the previous quarter

Key stats

What are the main financial stats of APLS
Market
Shares outstanding
106.52M
Market cap
$4.7B
Enterprise value
$4.28B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
9.33
Price to sales (P/S)
53.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
52.86
Earnings
Revenue
$80.94M
EBIT
-$682.47M
EBITDA
-$681.01M
Free cash flow
-$522.08M
Per share
EPS
-$7.95
Free cash flow per share
-$5.32
Book value per share
$4.73
Revenue per share
$0.83
TBVPS
$11.68
Balance sheet
Total assets
$1.15B
Total liabilities
$683.62M
Debt
$210.42M
Equity
$462.24M
Working capital
$979.21M
Liquidity
Debt to equity
0.46
Current ratio
8.85
Quick ratio
7.8
Net debt/EBITDA
0.62
Margins
EBITDA margin
-841.3%
Gross margin
98.2%
Net margin
-866.8%
Operating margin
-668%
Efficiency
Return on assets
-86.3%
Return on equity
-607.4%
Return on invested capital
-139.8%
Return on capital employed
-66.8%
Return on sales
-843.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

APLS stock price

How has the Apellis Pharmaceuticals stock price performed over time
Intraday
-0.52%
1 week
0.39%
1 month
3.61%
1 year
-30.42%
YTD
-6.62%
QTD
-13.11%

Financial performance

How have Apellis Pharmaceuticals's revenue and profit performed over time
Revenue
$80.94M
Gross profit
$79.5M
Operating income
-$540.68M
Net income
-$701.63M
Gross margin
98.2%
Net margin
-866.8%
APLS's operating income has dropped by 126% year-on-year
APLS's net income has dropped by 95% year-on-year but it is up by 6% since the previous quarter
The gross profit has shrunk by 68% YoY but it has increased by 20% QoQ
APLS's revenue has dropped by 68% year-on-year but it is up by 22% since the previous quarter

Growth

What is Apellis Pharmaceuticals's growth rate over time

Valuation

What is Apellis Pharmaceuticals stock price valuation
P/E
N/A
P/B
9.33
P/S
53.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
52.86
The EPS has dropped by 72% year-on-year but it is up by 10% since the previous quarter
The equity has surged by 133% since the previous quarter
The P/B is 45% less than the 5-year quarterly average of 17.1
APLS's revenue has dropped by 68% year-on-year but it is up by 22% since the previous quarter
The stock's price to sales (P/S) is 41% more than its last 4 quarters average of 38.2

Efficiency

How efficient is Apellis Pharmaceuticals business performance
APLS's ROE has shrunk by 151% YoY but it has soared by 90% QoQ
APLS's ROA has dropped by 105% year-on-year but it is up by 16% since the previous quarter
The return on sales is up by 23% since the previous quarter
The company's return on invested capital fell by 6% QoQ

Dividends

What is APLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for APLS.

Financial health

How did Apellis Pharmaceuticals financials performed over time
Apellis Pharmaceuticals's total assets is 68% more than its total liabilities
The company's quick ratio rose by 44% QoQ but it fell by 10% YoY
The company's current ratio rose by 42% QoQ but it fell by 4.3% YoY
The company's debt is 54% lower than its equity
The equity has surged by 133% since the previous quarter
The debt to equity has dropped by 94% year-on-year and by 57% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.